Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and ...
Parabilis Medicines, Inc.’s IPO spotlights Helicon peptide cancer drugs like zolucatetide, plus Regeneron’s $125M backing & ...
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...
Zacks Investment Research on MSN
Regeneron & Parabilis sign oncology collaboration worth up to $2.2B
Regeneron Pharmaceuticals REGN has entered into a strategic research collaboration with clinical-stage biopharmaceutical company Parabilis Medicines to develop multiple therapeutic candidates. The ...
Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.
Pharmaceutical Technology on MSN
Regeneron signs $2.32BN deal with Parabilis for Helicon conjugates
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates ...
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results